[go: up one dir, main page]

WO2011161970A1 - Anticorps anti-récepteur de pdgf - Google Patents

Anticorps anti-récepteur de pdgf Download PDF

Info

Publication number
WO2011161970A1
WO2011161970A1 PCT/JP2011/003603 JP2011003603W WO2011161970A1 WO 2011161970 A1 WO2011161970 A1 WO 2011161970A1 JP 2011003603 W JP2011003603 W JP 2011003603W WO 2011161970 A1 WO2011161970 A1 WO 2011161970A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
amino acid
seq
acid sequence
pdgfrα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2011/003603
Other languages
English (en)
Japanese (ja)
Inventor
清水　衛
順裕 丸山
克美 濱田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immuno Biological Laboratories Co Ltd
Original Assignee
Immuno Biological Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Biological Laboratories Co Ltd filed Critical Immuno Biological Laboratories Co Ltd
Publication of WO2011161970A1 publication Critical patent/WO2011161970A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention relates to an antibody that recognizes platelet-derived growth factor receptor ⁇ (hereinafter referred to as “PDGFR ⁇ ”) as an antigen and use thereof.
  • PDGFR ⁇ platelet-derived growth factor receptor ⁇
  • Part of the present invention relates to humanized anti-PDGFR ⁇ antibodies and uses thereof.
  • the present invention includes a gene that encodes an anti-PDGFR ⁇ antibody and a cell that produces the anti-PDGFR ⁇ antibody.
  • the use of the antibody is particularly used for treatment and diagnosis of a disease associated with PDGFR ⁇ activity, expression or overexpression.
  • Platelet-derived growth factor (hereinafter referred to as “PDGF”) is a protein that controls cell growth, differentiation, migration, and the like. There are four types of PDGF, A, B, C, and D. It is known that PDGF-A and PDGF-B have a homo- or hetero-dimer structure by disulfide bonds.
  • PDGFR ⁇ (also referred to as PDGFR2, CD140a), which is one of the subtypes of PDGF receptor, is a tyrosine kinase-related receptor.
  • PDGFR ⁇ can form a homodimer or a heterodimer with PDGFR ⁇ , a structurally similar PDGF receptor subtype.
  • PDGF-AA is known to have affinity only for PDGFR ⁇
  • PDGF-AB, PDGF-BB, and PDGF-CC are known to have affinity for both PDGFR ⁇ and PDGF ⁇ .
  • PDGFR ⁇ has been reported to be associated with diseases associated with cell proliferation such as tumors, stromal cells, and blood vessels (see Non-Patent Document 1).
  • ADCC activity antibody-dependent cytotoxic activity
  • CDC activity complement-dependent cytotoxic activity
  • the present invention relates to an anti-PDGFR ⁇ antibody having excellent ADCC activity, for example, an anti-PDGFR ⁇ antibody having an ADCC activity (%) of 25% or more.
  • the ADCC activity (%) exhibited by the anti-PDGFR ⁇ antibody of the present invention can be 30% or more, 35% or more, 40% or more, or 45% or more, and more preferably 50% or more.
  • “ADCC activity (%)” means ADCC activity compared to the control antibody of the test antibody, and 100 ⁇ ⁇ (measured value that is an index of ADCC activity obtained for the test antibody) / (control antibody) Measured value obtained as an index of ADCC activity) ⁇ ⁇ 100 (%).
  • the “control antibody” is not limited as long as it is an antibody known not to exhibit ADCC activity, and may be, for example, an anti-GST antibody. In the present specification, “ADCC activity (%)” may be simply referred to as “ADCC activity”.
  • the anti-PDGFR ⁇ antibody excellent in ADCC activity may be an antibody having ADCC activity equivalent to or higher than that of the 24A1 antibody.
  • an antibody having ADCC activity equivalent to that of the 24A1 antibody means that the ADCC activity compared to the control antibody of the test antibody (hereinafter referred to as “ADCC activity (%) of the test antibody”) is that of the 24A1 antibody. It is an antibody included in a range of ⁇ 20% of ADCC activity (hereinafter referred to as “ADCC activity (%) of 24A1 antibody”) compared with a control antibody.
  • an antibody having ADCC activity equal to or higher than that of the 24A1 antibody means an antibody in which the ADCC activity (%) of the test antibody is larger than the ADCC activity (%) of the 24A1 antibody.
  • the “control antibody” is not limited as long as it is an antibody known not to exhibit ADCC activity, and may be, for example, an anti-GST antibody.
  • the ADCC activity (%) of the 24A1 antibody is 100- ⁇ (measured value as an index of ADCC activity obtained for the 24A1 antibody) / (measured value as an index of ADCC activity obtained for the control antibody) ⁇ ⁇ 100 ( %).
  • the ADCC activity (%) of the test antibody is 100- ⁇ (measured value as an index of ADCC activity obtained for the test antibody) / (measured value as an index of ADCC activity obtained for the control antibody) ⁇ ⁇ It can be calculated by 100 (%). “The ADCC activity (%) of the test antibody falls within the range of ⁇ 20% of the ADCC activity (%) of the 24A1 antibody” means that the ADCC activity (%) of the test antibody is the ADCC activity (%) of the 24A1 antibody. It is included between 0.8 and 1.2 times.
  • an antibody having ADCC activity equivalent to that of the 24A1 antibody is such that the ADCC activity (%) of the test antibody is within ⁇ 15%, ⁇ 10%, or ⁇ 8% of the ADCC activity (%) of the 24A1 antibody. More preferably, it is an antibody contained within a range of ⁇ 5%. In the present specification, being contained within the range of ⁇ X% means -X% or more and + X% or less.
  • an antibody having ADCC activity equal to or higher than that of the 24A1 antibody has, for example, an ADCC activity (%) of the test antibody of ⁇ 20% or more, ⁇ 15% or more of the ADCC activity (%) of the 24A1 antibody, ⁇ 10 % Or more, ⁇ 8% or more, or ⁇ 5% or more of the antibody.
  • the anti-PDGFR ⁇ antibody having excellent ADCC activity may be an antibody having ADCC activity equivalent to or higher than that of the humanized 24A1 antibody.
  • the present invention relates to an anti-PDGFR ⁇ antibody excellent in CDC activity, for example, an anti-PDGFR ⁇ antibody having a CDC activity (%) of 10% or more.
  • the CDC activity (%) exhibited by the anti-PDGFR ⁇ antibody of the present invention can be 15% or more, or 20% or more, and more preferably 30% or more.
  • the CDC activity (%) means the CDC activity compared to the control antibody of the test antibody, and 100- ⁇ (measured value that is an index of CDC activity obtained for the test antibody) / (obtained for the control antibody). Measured value that is an index of CDC activity) ⁇ ⁇ 100 (%).
  • the “control antibody” is not limited as long as it is an antibody known not to exhibit CDC activity, and may be, for example, an anti-GST antibody. In the present specification, “CDC activity (%)” may be simply referred to as “CDC activity”.
  • the anti-PDGFR ⁇ antibody excellent in CDC activity may be an antibody having CDC activity equivalent to or higher than that of 21A1 antibody.
  • an antibody having a CDC activity equivalent to that of the 21A1 antibody means that the CDC activity compared to the control antibody of the test antibody (hereinafter referred to as “CDC activity (%) of the test antibody”) is that of the 21A1 antibody. It is an antibody that is included within a range of ⁇ 20% of the CDC activity compared to the control antibody (hereinafter referred to as “CDC activity (%) of 21A1 antibody”).
  • the “CDC activity equal to or higher than that of the 21A1 antibody” means an antibody in which the CDC activity (%) of the test antibody is larger than the CDC activity (%) of the 21A1 antibody.
  • the control antibody is not limited as long as it is an antibody known not to exhibit CDC activity, and may be, for example, an anti-GST antibody.
  • the CDC activity (%) of 21A1 antibody is ⁇ (measured value as an index of CDC activity obtained for 21A1 antibody) / (measured value as an index of CDC activity obtained for antibody non-administered group) ⁇ ⁇ 100 ( %).
  • the CDC activity (%) of the test antibody is ⁇ (measured value as an index of CDC activity obtained for the test antibody) / (measured value as an index of CDC activity obtained for the antibody non-administered group) ⁇ ⁇ It can be calculated by 100 (%). “The CDC activity (%) of the test antibody falls within the range of ⁇ 20% of the CDC activity (%) of the 21A1 antibody” means that the CDC activity (%) of the test antibody is the CDC activity (%) of the 21A1 antibody. It is included within the range of 0.8 to 1.2 times.
  • an antibody having CDC activity equivalent to 21A1 antibody is such that the CDC activity (%) of the test antibody is within ⁇ 15%, ⁇ 10%, or ⁇ 8% of the CDC activity (%) of 21A1 antibody. More preferably, it is an antibody contained within a range of ⁇ 5%. Therefore, an antibody having a CDC activity equal to or higher than that of the 21A1 antibody has, for example, a CDC activity (%) of the test antibody of ⁇ 20% or more, ⁇ 15% or more of the CDC activity (%) of the 21A1 antibody, ⁇ 10 % Or more, ⁇ 8% or more, or ⁇ 5% or more of the antibody.
  • the anti-PDGFR ⁇ antibody excellent in CDC activity exhibits appropriate ADCC activity in addition to CDC activity.
  • an anti-PDGFR ⁇ antibody having a CDC activity (%) of 10% or more and an ADCC activity (%) of 25% or more can be mentioned.
  • the CDC activity (%) in an antibody excellent in CDC activity and ADCC activity can be 10% or more, 15% or more, or 20% or more, and more preferably 30% or more.
  • the ADCC activity (%) in an antibody excellent in CDC activity and ADCC activity can be 25% or more, 30% or more, 35% or more, 40% or more, or 45% or more, more preferably 50%. % Or more.
  • the antibody excellent in CDC activity and ADCC activity may be an antibody having CDC activity and ADCC activity equivalent to or higher than 21A1 antibody.
  • whether the subject antibody has CDC activity equal to or higher than 21A1 antibody and ADCC activity equal to or higher than 21A1 antibody can be determined according to the above-described method.
  • the present invention relates to an antibody that recognizes a specific epitope of PDGFR ⁇ , specifically, an anti-PDGFR ⁇ antibody that recognizes the amino acid sequence from position 106 to 311 of PDGFR ⁇ (SEQ ID NO: 1) as an epitope, Relates to an anti-PDGFR ⁇ antibody that recognizes the 106th to 213rd amino acid sequence (SEQ ID NO: 2) of PDGFR ⁇ or the 213th to 311th amino acid sequence (SEQ ID NO: 3) of PDGFR ⁇ as an epitope.
  • an anti-PDGFR ⁇ antibody that recognizes the amino acid sequence from position 106 to 311 of PDGFR ⁇ (SEQ ID NO: 1) as an epitope
  • an anti-PDGFR ⁇ antibody that recognizes the amino acid sequence from 213 to 311 of PDGFR ⁇ (SEQ ID NO: 3) as an epitope is particularly excellent in ADCC activity, and thus is useful for the treatment of diseases caused by cell proliferation (for example, tumors). is there.
  • an anti-PDGFR ⁇ antibody that recognizes the amino acid sequence from 213 to 311 of PDGFR ⁇ (SEQ ID NO: 3) as an epitope further has ADCC activity of 25% or more, 30% or more, 35% or more, 40% or more, 45% Or 50% or more.
  • the anti-PDGFR ⁇ antibody that recognizes the amino acid sequence from 213 to 311 of PDGFR ⁇ (SEQ ID NO: 3) as an epitope may have ADCC activity equal to or higher than that of the 24A1 antibody.
  • the amino acid recognized by an antibody that recognizes a specific epitope of PDGFR ⁇ may be a part of the amino acid sequence that constitutes the epitope.
  • the amino acid recognized by the antibody may be 3 amino acids or more selected from amino acids constituting the epitope.
  • the present inventors have found an antibody having a sequence excellent in antitumor activity. Therefore, in another aspect, the present invention relates to an antibody specified by the amino acid sequence of a complementarity determining region (hereinafter referred to as “CDR”).
  • CDR refers to Kabat et al. (“Sequences of Proteins of Immunological Interest”, Kabat, E. et al., U.S. Department of Health and Human Services, Cho & L et al., 1983). Mol. Biol., 196, 901-917, 1987).
  • CDR1, CDR2, and CDR3 of the heavy chain are respectively SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, or SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO:
  • the present invention relates to an antibody having the amino acid sequence of No. 36.
  • the light chain CDR1, CDR2, and CDR3 are respectively represented by SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9, or SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38. It relates to an antibody having the amino acid sequence described.
  • the present invention provides that the heavy chain CDR1, CDR2, and CDR3 have the amino acid sequences set forth in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively, and the light chain CDR1.
  • CDR2 and CDR3 have the amino acid sequences set forth in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, or heavy chain CDR1, CDR2 and CDR3 are respectively SEQ ID NO: 33
  • the amino acids having the amino acid sequences described in SEQ ID NO: 34 and SEQ ID NO: 35, and the light chain CDR1, CDR2, and CDR3 are described in SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38 An antibody having a sequence.
  • the antibody of the present invention is an antibody in which the amino acid sequences of heavy and light chains are specified, and includes the following antibodies: (I) an antibody whose heavy chain variable region (hereinafter referred to as “VH”) has an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions with a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 10; (Ii) an antibody having an amino acid sequence encoded by a nucleic acid sequence in which a light chain variable region (hereinafter referred to as “VL”) hybridizes with a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 11 under stringent conditions; (Iii) an antibody having both a VH of (i) and a VL of (ii); (Iv) an antibody in which VH has an amino acid sequence having 80%, 85%, 90%, 95%, 98%, or 99% homology with the amino acid sequence of SEQ ID NO: 10; (V) an antibody where
  • the antibodies (i) to (vi) are antibodies that bind to PDGFR ⁇ , and preferably have cell growth inhibitory activity. Of these antibodies, most preferred is an antibody in which the heavy chain has the amino acid sequence of SEQ ID NO: 10 and the light chain has the amino acid sequence of SEQ ID NO: 11.
  • the antibodies (i) to (vi) may have CDC activity of 10% or more, 15% or more, or 20% or more, 30% or more, and / or ADCC activity of 25% or more, It may be 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more.
  • 24A1 antibody refers to an antibody in which the heavy chain consists of the amino acid sequence set forth in SEQ ID NO: 30 and the light chain consists of the amino acid sequence set forth in SEQ ID NO: 32 unless otherwise specified. is there.
  • “Humanized 24A1 antibody” has the sequences of SEQ ID NOs: 4, 5, and 6 as heavy chain CDRs 1, 2, and 3, respectively, and the sequences of SEQ ID NOs: 7, 8, and 9, respectively. It refers to an antibody having as light chain CDRs 1, 2 and 3.
  • the “humanized 24A1 antibody” is an antibody whose heavy chain consists of the amino acid sequence set forth in SEQ ID NO: 24 and whose light chain consists of the amino acid sequence set forth in SEQ ID NO: 26.
  • 21A1 antibody means the 21A1 antibody obtained in Example 1 of the present specification, unless specifically stated otherwise.
  • the heavy chain is derived from the amino acid sequence set forth in SEQ ID NO: 40.
  • the light chain is an antibody consisting of the amino acid sequence set forth in SEQ ID NO: 42.
  • the “humanized 21A1 antibody” has the sequences of SEQ ID NOs: 33, 34, and 35 as the heavy chain CDRs 1, 2, and 3, respectively, and the sequences of SEQ ID NOs: 36, 37, and 38, respectively. It refers to an antibody having as light chain CDRs 1, 2 and 3. .
  • the ADCC activity (%) and CDC activity (%) of the 24A1 antibody and the 21A1 antibody can be measured by the measurement method described in the present specification after preparing the antibody. ) Can be determined by referring to the description.
  • the antibodies of the present invention further include the following antibodies: An anti-PDGFR ⁇ antibody satisfying at least one of the following (A) to (C): (A) an anti-PDGFR ⁇ antibody that recognizes the amino acid sequence of any one of SEQ ID NO: 1 to SEQ ID NO: 3 as an epitope; (B) The heavy chain CDR1, CDR2, and CDR3 have the amino acid sequences set forth in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively, and / or the light chain CDR1, CDR2 And CDR3 are the antibodies having the amino acid sequences set forth in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively, or heavy chain CDR1, CDR2 and CDR3 are respectively SEQ ID NO: 33.
  • SEQ ID NO: 34, and SEQ ID NO: 35, and / or light chain CDR1, CDR2, and CDR3 are SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: An antibody having the amino acid sequence described in 38; or (C) the antibody according to any one of (i) to (vi), And an antibody exhibiting one or more properties selected from the following (a) to (e): (A) ADCC activity (%) is 25% or more, 30% or more, 35% or more, 40% or more, 45%, or 50% or more; (B) has ADCC activity equal to or greater than 24A1 antibody or humanized 24A1 antibody; (C) CDC activity (%) is 10% or more, 15% or more, 20% or more, or 30% or more; (D) has ADCC and CDC activity equal to or higher than 21A1 antibody; or (E) It binds to PDGFR ⁇ with a dissociation constant (Kd) of 7 ⁇ 10 ⁇ 9 or less, 6.5 ⁇ 10 ⁇ 9 or less, or
  • hybridize under stringent conditions means to hybridize under hybridization conditions usually used by those skilled in the art. For example, whether or not to hybridize can be determined by a method described in Molecular Cloning, Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989).
  • hybridization conditions are 6 ⁇ SSC (0.9 M NaCl, 0.09 M trisodium citrate) or 6 ⁇ SSPE (3 M NaCl, 0, 2 M NaH 2 PO 4 , 20 mM EDTA ⁇ 2Na, pH 7.4).
  • the condition may be such that the medium is hybridized at 42 ° C. and then washed at 42 ° C. with 0.5 ⁇ SSC.
  • the homology of an amino acid sequence can be determined using well-known programs, such as BLAST and FASTA, for example.
  • the present invention relates to the following (1) to (17).
  • An anti-PDGFR ⁇ antibody whose ADCC activity (%) by T cells is 25% or more.
  • An anti-PDGFR ⁇ antibody having ADCC activity equal to or higher than that of the 24A1 antibody.
  • the anti-PDGFR ⁇ antibody according to (5) wherein the ADCC activity (%) by T cells is 25% or more.
  • the anti-PDGFR ⁇ antibody according to any one of (3) to (5) which recognizes an amino acid sequence contained in the 106th to 311th amino acid sequences of PDGFR ⁇ as an epitope.
  • the anti-PDGFR ⁇ antibody according to any one of (3) to (5) which recognizes the amino acid sequence contained in the amino acid sequence described in SEQ ID NO: 1 or SEQ ID NO: 2 as an epitope.
  • the heavy chain CDR1 has the amino acid sequence set forth in SEQ ID NO: 4, the heavy chain CDR2 has the amino acid sequence set forth in SEQ ID NO: 5, and the heavy chain CDR3 has the amino acid sequence set forth in SEQ ID NO: 6 And / or the light chain CDR1 has the amino acid sequence set forth in SEQ ID NO: 7, the light chain CDR2 has the amino acid sequence set forth in SEQ ID NO: 8, and / or A light chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 9, or a heavy chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 33 and a heavy chain CDR2 set forth in SEQ ID NO: 34.
  • the heavy chain CDR3 has the amino acid sequence set forth in SEQ ID NO: 35 and / or the light chain CDR1 has the amino acid sequence set forth in SEQ ID NO: 36, CDR2 of the chain is arranged
  • variable region of the heavy chain has one amino acid sequence selected from: The amino acid sequence encoded by the nucleic acid sequence that hybridizes under stringent conditions with the nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 10; An amino acid sequence having 80%, 85%, 90%, 95%, 98%, or 99% homology with the amino acid sequence of SEQ ID NO: 10; or The amino acid sequence of SEQ ID NO: 10, and / or (II)
  • the light chain variable region has one amino acid sequence selected from: A nucleic acid sequence that hybridizes under stringent conditions with a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 11; An amino acid sequence having 80%, 85%, 90%, 95%, 98%, or 99% homology with the amino acid sequence of SEQ ID NO: 11; or The amino acid sequence of SEQ ID NO: 11, An antibody capable of binding to PDGF ⁇ .
  • the anti-PDGFR ⁇ antibody according to any one of claims 1 to 7, which binds to PDGFR ⁇ with a dissociation constant (Kd) of 7 ⁇ 10 ⁇ 9 or less.
  • a pharmaceutical composition comprising the antibody according to any one of (1) to (11) or (14) to (16).
  • the amino acid sequence described in any one of SEQ ID NO: 1 to SEQ ID NO: 3 is recognized as an epitope, and ADCC activity (%) is 25% or more, 30% or more, 35% or more, 40% An anti-PDGFR ⁇ antibody that is 45% or more, or 50% or more.
  • the amino acid sequence described in any one of SEQ ID NO: 1 to SEQ ID NO: 3 is recognized as an epitope, and the CDC activity (%) is 10% or more, 15% or more, 20%, or 30% Anti-PDGFR ⁇ antibody as described above.
  • the amino acid sequence described in any one of SEQ ID NO: 1 to SEQ ID NO: 3 is recognized as an epitope, and ADCC activity (%) is 25% or more, 30% or more, 35% or more, 40% Or more, 45% or more, or 50% or more, and an antibody whose CDC activity (%) is 10% or more, 15% or more, 20%, or 30% or more.
  • the “antibody” includes non-human animal antibodies, antibodies having the amino acid sequences of non-human animal antibodies and human antibodies, and human antibodies.
  • An antibody having an amino acid sequence of a non-human animal antibody and an amino acid sequence of a human antibody is a human chimeric antibody obtained by replacing the antigen-binding domain Fv of a human antibody with the antigen-binding domain Fv of a non-human animal monoclonal antibody. It includes humanized antibodies in which CDRs are incorporated into the frame region of human antibodies (hereinafter referred to as “FR”).
  • the immunoglobulin class of the antibody of the present invention is not particularly limited, and may be any immunoglobulin class of IgG, IgM, IgA, IgE, IgD, and IgY.
  • the antibody of the present invention encompasses antibodies of any isotype.
  • the antibody of the present invention may be a polyclonal antibody or a monoclonal antibody.
  • the term “antibody” refers to a full-length antibody, an antibody fragment (F (ab ′) 2 , Fab ′, Fab, scFv, dsFv or a polymer thereof, Diabody, etc., and CDR). Including peptides).
  • the “disease caused by cell proliferation” is a disease that substantially develops or worsens due to cell proliferation, and includes, for example, tumors (cancer, sarcoma). .
  • the present invention also includes DNA having a nucleic acid sequence encoding the above antibody (including antibody fragments), a vector having the DNA, a host cell having the vector, and the like.
  • the present invention includes DNA having the nucleic acid sequence described in SEQ ID NO: 23 and / or 25, or SEQ ID NO: 29 and / or 31, a vector having the DNA, a host cell having the vector, and the like.
  • the present invention also relates to a DNA having a nucleic acid sequence that hybridizes under stringent conditions with the nucleic acid sequence of 23 and / or 25 or SEQ ID NO: 29 and / or 31, a vector having the DNA, and It includes a host cell having a vector.
  • the present invention has 80%, 85%, 90%, 95%, 98%, or 99% homology with the nucleic acid sequence shown in 23 and / or 25 or SEQ ID NO: 29 and / or 31. It includes a DNA having a nucleic acid sequence, a vector having the DNA, a host cell having the vector, and the like. Further, according to the present invention, the heavy chain CDR1, CDR2, and CDR3 have the amino acid sequences set forth in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively, and / or the light chain.
  • CDR1, CDR2, and CDR3 are antibodies having the amino acid sequences described in SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9, respectively, or heavy chain CDR1, CDR2, and CDR3 are respectively Having the amino acid sequence set forth in SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35, and / or the light chain CDR1, CDR2, and CDR3 are SEQ ID NO: 36, SEQ ID NO: 37, and DNA encoding an antibody having the amino acid sequence set forth in SEQ ID NO: 38, a vector having the DNA, a host cell having the vector, and the like .
  • DNA having the nucleic acid sequence hybridizing under stringent conditions with the above-described DNA (SEQ ID NO: 29 and / or 31), or 23 and / or 25, or SEQ ID NO: 29 and / or 31
  • Any of the nucleic acid sequences described herein, including DNA having a nucleic acid sequence having 80%, 85%, 90%, 95%, 98%, or 99% homology, is preferably encoded by the sequence.
  • the antibody binds to PDGFR ⁇ , and more preferably, the antibody encoded by the sequence exhibits one or more properties selected from the following (a) to (e): (A) ADCC activity is 25% or more, 30% or more, 35% or more, 40% or more, 45%, or 50% or more; (B) has ADCC activity equal to or greater than 24A1 antibody or humanized 24A1 antibody; (C) CDC activity is 10% or more, 15% or more, 20% or more, or 30% or more; (D) has ADCC and CDC activity equal to or higher than 21A1 antibody; or (E) It binds to PDGFR ⁇ with a dissociation constant (Kd) of 7 ⁇ 10 ⁇ 9 or less, 6.5 ⁇ 10 ⁇ 9 or less, or 6.2 ⁇ 10 ⁇ 9 or less.
  • Kd dissociation constant
  • the antibody of the present invention can exhibit an excellent PDGFR ⁇ activity inhibitory action.
  • the antibody of the present invention since the antibody of the present invention is excellent in ADCC activity and / or CDC activity, it can exhibit a superior cell killing effect on PDGFR ⁇ -expressing cells. Therefore, the antibody of the present invention can be used as a therapeutic or prophylactic agent for a disease associated with the onset or exacerbation of PDGFR ⁇ mutation or expression, particularly a disease (tumor etc.) caused by cell proliferation.
  • each lane in each photograph shows normal mouse IgG (negative control), monoclonal antibodies 1A1, 5A1, 8A1, 9A1, 10A1, 18A1, 21A1, 22A1, 24A1, 40A1, and PDGF-AA administered cells, and PDGF -AA untreated cells, PDGF-AA treated cells.
  • the number on the left of each photograph indicates the molecular weight (kDa).
  • the vertical axis represents ADCC activity (%), and the horizontal axis represents the clone number of each monoclonal antibody. It is a graph which shows the result of having measured the CDC activity of the antibody of this invention.
  • the vertical axis represents CDC activity (%), and the horizontal axis represents the clone number of each monoclonal antibody.
  • Each monoclonal antibody was administered at 5 ⁇ g / mL (black) or 1 ⁇ g / mL (white). It is a graph which shows the result of having measured the antitumor effect of the antibody of this invention using the nude mouse.
  • the vertical axis represents tumor size (mm 3 ), and the horizontal axis represents elapsed time (weeks). The upward arrow below the horizontal axis indicates the time when the antibody was administered.
  • the vertical axis represents tumor size (mm 3 ), and the horizontal axis represents elapsed time (weeks).
  • the upward arrow below the horizontal axis indicates the time when the antibody was administered.
  • Each symbol indicates the following specimen: black diamond is 1 mg administration group; black square is 0.4 mg administration group; black triangle is 0.1 mg administration group; cross is control antibody (40B3) (0.4 mg) administration group.
  • It is a schematic diagram of a fusion protein of each deletion mutant of PDGFR ⁇ and Fc used for epitope mapping by dot blot. It is a photograph which shows the result of the epitope mapping by a dot blot.
  • the upper part of the photograph shows the antibody used, and the left part of the photograph shows the Fc fusion protein or control (mIgG2aFc) of the deletion mutant of PDGFR ⁇ used. It is the photograph which confirmed the expression of the heavy chain (Hc) and light chain (Lc) of the cloned monoclonal antibodies 21A1 and 24A1 by Western blotting.
  • Cell Pellet at the top of the photograph refers to a cell pellet sample
  • “Sup ( ⁇ 10)” refers to a sample obtained by concentrating the cell culture supernatant 10 times.
  • Each lane of Cell Pellet and Sup ( ⁇ 10) is from the left, pcDNA vector alone (negative control), Hc of monoclonal antibody 21A1, Lc of monoclonal antibody 21A1, Hc + Lc of monoclonal antibody 21A1, Hc of monoclonal antibody 24A1, monoclonal antibody Lc of 24A1 and Hc + Lc of monoclonal antibody 24A1 are shown.
  • the number on the left of the photo indicates the molecular weight (kDa).
  • the arrow head on the right side of the photograph shows the position corresponding to the molecular weight of Hc and Lc proteins. It is the figure which compared the amino acid sequence of Hc of monoclonal antibody 24A1, humanized 24A1 antibody, and IGHV4-30-4.
  • FIG. 4 is a diagram comparing the amino acid sequences of Lc of monoclonal antibody 24A1, humanized 24A1 antibody, and IGKV 1D-12. It is the photograph which confirmed the expression of the produced heavy chain 24A1 antibody and the heavy chain (Hc) and light chain (Lc) of humanized 24A1 antibody by Western blotting. “Cell Pellet” at the top of the photograph refers to a cell pellet sample, and “Sup ( ⁇ 10)” refers to a sample obtained by concentrating the cell culture supernatant 10 times.
  • Each lane of Cell Pellet and Sup ( ⁇ 10) is, from the left, pcDNA vector alone (negative control), Hc of chimeric 24A1 antibody, Lc of chimeric 24A1 antibody, Hc + Lc of chimeric 24A1 antibody, Hc of humanized 24A1 antibody, human The Lc of the 24A1 antibody and Hc + Lc of the humanized 24A1 antibody are shown.
  • the number on the left of the photo indicates the molecular weight (kDa).
  • the arrow head on the right side of the photograph shows the position corresponding to the molecular weight of Hc and Lc proteins.
  • the antibody of the present invention can be obtained by the following method. First, an expression vector for mammalian cells incorporating a polynucleotide encoding a polypeptide having all or part of PDGFR ⁇ is prepared and expressed to obtain an antigen.
  • an animal such as a mouse, rat or rabbit is immunized using this antigen according to a known method for producing a monoclonal antibody.
  • immune cells obtained from the immunized animal and myeloma cells are fused to obtain a hybridoma, and a PDGFR ⁇ monoclonal antibody can be obtained from the hybridoma culture.
  • the animal When preparing a polyclonal antibody, the same antigen as described above is used, the animal is immunized according to a known method of polyclonal antibody preparation, blood is collected from the immunized animal, and PDGFR ⁇ polyclonal antibody is collected from the blood from the serum. Obtainable.
  • the PDGFR ⁇ used as the immunogen is not particularly limited as long as it is a mammalian PDGFR ⁇ , but is preferably human PDGFR ⁇ .
  • human PDGFR ⁇ has been reported for its entire amino acid sequence (SEQ ID NO: 13) and cDNA sequence (SEQ ID NO: 12).
  • DNA encoding a polypeptide that matches all or part of PDGFR ⁇ can also be obtained by cloning from a mammalian library such as a human tumor cell line using a mammal-derived PDGFR ⁇ DNA as a probe.
  • the immunogen used for producing the antibody of the present invention is an expression vector containing DNA encoding PDGFR ⁇ or a part thereof (for example, pGEX (for E.
  • coli pcDNA3.1 (for animal cell expression), etc.) It can be obtained by transforming into insect cells, animal cells, etc., and culturing and expressing the transformed host microorganism / cultured cells such as Escherichia coli in an appropriate medium (for example, LB medium).
  • an appropriate medium for example, LB medium
  • a peptide having a part of PDGFR ⁇ can be used as it is, or a peptide having a part of one or more kinds of PDGFR ⁇ , It can also be used by binding via a linker.
  • a peptide having PDGFR ⁇ or a part thereof can be prepared using a known method such as the Fmoc method or the Boc method, or an automatic peptide synthesizer.
  • the immunogen includes an extracellular region of PDGFR ⁇ , preferably the amino acid described in any one of SEQ ID NO: 1 to SEQ ID NO: 3. Contains an array.
  • an immunogen for example, for example, PDGFR ⁇ extracellular region (1-514 amino acids) (SEQ ID NO: 14) and mouse IgG2a constant region fusion protein (PDGFR ⁇ -Fc) can be used as antigens.
  • the animal is immunized with the antigen by dissolving the antigen in a sodium phosphate buffer (PBS) and, if necessary, an immunostimulant (eg, mineral oil or aluminum precipitate and heat-killed bacteria or lipopolysaccharide, Freund's). Immunization of non-human mammals or birds with a complete adjuvant or Freund's incomplete adjuvant.
  • Administration of the immunogen to the animal can be performed, for example, by subcutaneous injection, intraperitoneal injection, intravenous injection, intramuscular injection, or footpad injection.
  • the amount of the immunogen used is not particularly limited as long as it is an amount capable of producing an antibody, but is preferably 0.1 to 1000 ⁇ g, more preferably 1 to 500 ⁇ g, and still more preferably 10 to 100 ⁇ g. Immunization can be performed once or several times at appropriate intervals. Preferably, immunization once per 1 to 5 weeks can be performed a plurality of times (preferably 2 to 5 times in total). An antibody can be obtained by purifying from the serum of an animal exhibiting a sufficient antibody titer.
  • the monoclonal antibody of the present invention can be obtained by culturing a hybridoma obtained by fusing an antibody-producing cell obtained from the spleen or the like of an immunized animal immunized by the above method with a myeloma cell (myeloma cell). Can do.
  • Examples of the fusion method include the method of Milstein et al. (Galfre, G. & Milstein, C., Methods Enzymol. 73: 3-46, 1981).
  • the antibody can be obtained by culturing the hybridoma in vitro and purifying the culture solution.
  • the antibody can also be obtained by transplanting a hybridoma to a syngeneic animal or an immunodeficient animal to which pristane has been administered intraperitoneally in advance, then ascites, and purifying the collected ascites. Purification of the antibody can be obtained by collecting the IgG fraction using a protein A column, protein G column or the like after centrifugation.
  • the antibody class is IgY or IgM
  • the antibody can be purified by a column using mercaptopyridine as a ligand.
  • it can be purified using a PDGFR ⁇ solid phase column, ion exchange chromatography, hydrophobic interaction chromatography or the like regardless of the class of antibody.
  • the human chimeric antibody of the present invention is prepared by preparing DNAs encoding VH and VL of non-human animal monoclonal antibodies that bind to PDGFR ⁇ , which are combined with human immunoglobulin constant region cDNA and incorporated into an expression vector. It can be obtained by introducing the vector into a host cell and expressing it (Morrison, SL, et al., Proc. Natl. Acad. Sci. USA, 81, 6851-6855, 1984).
  • the humanized antibody of the present invention constructs a DNA encoding a V region in which amino acid sequences encoding CDRs of VH and VL of a non-human animal monoclonal antibody that binds to PDGFR ⁇ are grafted on VH and VL of human antibodies,
  • the constructed DNA can be obtained by binding to a constant region cDNA of human-derived immunoglobulin and incorporating it into an expression vector, and introducing the vector into an appropriate host cell for expression (L. Rieohmann et al., Nature, 332). 323, 1988: Kettleborough, CA et al., Protein Eng., 4, 773-783, 1991; Clark M., Immunol. Today., 21, 397-402, 2000).
  • the CDR of the non-human animal monoclonal antibody includes the amino acid sequence predicted from the DNA sequence encoding the VH and VL of the non-human animal monoclonal antibody obtained by the above-described method, the entire amino acid sequence of VH and VL of the known antibody, Can be obtained by comparing.
  • the amino acid sequence of a known antibody can be obtained from the amino acid sequence of an antibody registered in a database such as a protein data bank.
  • CDR1, CDR2 and CDR3 of the heavy chain are respectively described in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, or SEQ ID NO: 33, SEQ ID NO: 34 and SEQ ID NO: 35, respectively.
  • CDR1, CDR2 and CDR3 are the amino acid sequences set forth in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively, or SEQ ID NO: 36, respectively. It has the amino acid sequence set forth in SEQ ID NO: 37 and SEQ ID NO: 38.
  • the heavy chain CDR1, CDR2, and CDR3 are each composed of the amino acid sequences set forth in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, and the light chain CDR1, CDR2, and CDR3 are respectively It consists of the amino acid sequences described in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, or the heavy chain CDR1, CDR2 and CDR3 are the amino acids described in SEQ ID NO: 33, SEQ ID NO: 34 and SEQ ID NO: 35, respectively.
  • the light chain CDR1, CDR2, and CDR3 are amino acid sequences described in SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38, respectively.
  • variable region of a humanized antibody is a CDR.
  • Human antibody FR having a three-dimensional structure similar to that of the V region of the non-human animal monoclonal antibody derived from or human antibody FR having high homology with the FR amino acid sequence of the non-human animal monoclonal antibody used.
  • Whether or not the V region of the humanized antibody having the FR of the selected human antibody has a three-dimensional structure similar to the V region of the non-human animal monoclonal antibody from which the CDR is derived can be determined by, for example, determining the FR and non- The three-dimensional structure can be predicted by computer modeling based on the DNA sequence information of the V region containing the CDR of the human animal monoclonal antibody and compared with the three-dimensional structure of the V region of the non-human animal monoclonal antibody from which the CDR is derived. it can.
  • the FR amino acid sequence of the non-human animal monoclonal antibody can be obtained from the VH and VL amino acid sequences and the CDR amino acid sequence information obtained by the above-described method.
  • the V region of a humanized antibody can also be designed by appropriately mutating the FR amino acid sequence of a human antibody.
  • the antibody of the present invention preferably has the amino acid sequences described in SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18 as heavy chains FR1, FR2, FR3 and FR4, respectively.
  • the antibody of the present invention preferably has the amino acid sequences described in SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22 as the light chains FR1, FR2, FR3 and FR4.
  • the DNA sequence encoding the V region of the humanized antibody to be used is designed as a DNA sequence corresponding to the amino acid sequence obtained by combining the CDR amino acid sequence of the non-human animal monoclonal antibody and the FR amino acid sequence of the human antibody.
  • DNA encoding the V region of a humanized antibody can be prepared by a method well known to those skilled in the art based on the designed DNA sequence. For example, it can be obtained by chemically synthesizing a DNA fragment having a length of about 100 bp as a synthetic DNA based on the designed DNA and amplifying the DNA fragment by PCR.
  • DNA fragment of about 100 bp is bound using an enzyme such as ligase, PCR is performed using primers encoding the sequences at both ends of the designed DNA sequence encoding the V region of the humanized antibody, It can also be obtained by extracting a DNA fragment having a length of.
  • DNA encoding the V region of a humanized antibody used for PCR can also be obtained by a method known as CDR grafting.
  • the DNA encoding the V region of the humanized antibody to be used can also be obtained by incorporating a DNA encoding CDR into the DNA of the V region of the human antibody by site-directed mutagenesis.
  • Site-specific mutations include, for example, Gene Taylor Site-Directed Mutagenesis System (Gene Taylor Site-Directed Mutagenesis System (Invitrogen)), Transformer Site-Directed Mutagenesis Kit (Clontech), Site Directed A mutagenesis system (Site-Directed Mutagenesis System) (Takara Bio Inc.) or the like can be used by following the description of the kit.
  • VH comprises the amino acid sequence of SEQ ID NO: 10 and / or VL comprises the amino acid sequence of SEQ ID NO: 11.
  • human antibodies CH and CL used in the preparation of humanized antibodies any human antibody CH and CL can be used. Examples include human ⁇ 1, ⁇ 2 CH and human ⁇ CL.
  • a gene encoding CH and CL of a human antibody chromosomal DNA or cDNA can be used.
  • the DNA encoding the V region of the humanized antibody obtained by the above-described method is bound to, for example, DNA encoding human antibody CH and CL, respectively, and incorporated into an expression vector for animal cells.
  • a vector that expresses the conjugated antibody can be prepared.
  • enhancers and promoters used for expression of humanized antibodies include enhancers and promoters of immunoglobulin genes themselves or non-immunoglobulin enhancers and promoters.
  • an expression vector for animal cells for example, pSV2-gpt (RC Mulligan and P. Berg, Science, 209, 1422, 1980) can be used.
  • the genes encoding the H chain and L chain of the humanized antibody of the present invention produced by the above method may be incorporated into the same vector or into different vectors.
  • Human antibodies can be obtained, for example, by using a human antibody phage library or a human antibody-producing transgenic mouse (Tomitsuka et al., Nature Genet., 15, 146-156 (1997)).
  • the human antibody phage library allows human antibody Fab or scFv to be displayed on the surface as a fusion protein by introducing the VH gene and VL gene from the antibody gene pool having various sequences derived from human B cells into the phage gene.
  • a phage library As such a human antibody phage library, naive / non-immune obtained by amplifying the VH gene and VL gene of a normal human antibody from peripheral blood lymphocytes by RT-PCR and making it into a library.
  • a human antibody phage library for example, PDGFR ⁇ or a peptide having an epitope sequence recognized by the antibody of the present invention is immobilized on a solid phase, the phage antibody library is reacted, and unbound phage is washed away. Thereafter, the desired phage can be obtained (panning) by recovering the bound phage. Moreover, the accuracy of the obtained clone can be raised by amplifying the obtained phage and repeatedly performing panning for the amplified library. By analyzing the VH gene and VL gene of the obtained clone, a complete human antibody having these gene sequences can be prepared.
  • a human antibody-producing transgenic mouse is a mouse in which an Ig gene of a human antibody is introduced into a mouse in which an endogenous immunoglobulin (Ig) gene is knocked out.
  • a human antibody-producing transgenic mouse can be obtained, for example, by the following method.
  • a human-mouse hybrid cell is treated with colcemid (spindle formation inhibitor) for 48 hours to form a microcell, which is a structure in which one to several chromosomes are enveloped in the nuclear membrane.
  • Microcells isolated in the presence of cytochalasin B are fused with chromosome recipient cells (mouse ES cells) with polyethylene glycol to produce microcell hybrid ES cells, which are injected into mouse embryos.
  • an anti-PDGFR ⁇ human antibody is obtained. Obtainable.
  • An F (ab ′) 2 fragment (an antibody fragment having an antigen binding activity with a molecular weight of about 100,000) is obtained by cleaving at the 234th amino acid residue of the H chain by treating the IgG antibody of the present invention with pepsin. be able to.
  • the Fab ′ fragment can be obtained by treating F (ab ′) 2 obtained by the above-described method with dithiothreitol.
  • the Fab ′ fragment of the present invention can be obtained from DNA encoding Fab ′ of the antibody of the present invention.
  • Fab fragments (antibody fragments having an antigen binding activity of about 50,000 molecular weight in which about half of the region on the N-terminal side of the H chain and all regions of the L chain are bound by disulfide bonds) are treated with papain. By doing so, it can be obtained by cleaving at the 224th amino acid residue of the H chain.
  • the Fab fragment of the present invention can be obtained from DNA encoding the Fab of the antibody of the present invention.
  • the scFv can be obtained by inserting a DNA encoding a linker sequence between cDNAs encoding the VH and VL of the antibody of the present invention to construct a DNA encoding scFv.
  • the length of the linker is not particularly limited as long as VH and VL can associate with each other, but is preferably 10 to 20 residues, and more preferably 15 residues.
  • the linker sequence is not particularly limited as long as it does not inhibit folding of the polypeptide chains of the two domains of VH and VL, but is preferably a linker composed of glycine and / or serine, more preferably , GGGGS (G: glycine, S: serine) or a repetitive sequence thereof.
  • dsFv can be obtained by substituting one cysteine residue in each of VH and VL with a cysteine residue and connecting the cysteine residues with a disulfide bond.
  • Diabody can be obtained by constructing the above-mentioned scFv-encoding DNA such that the amino acid sequence of the linker is 8 residues or less (preferably 5 residues).
  • Bispecific diabody can be obtained by preparing scFv by combining VH and VL DNAs of two different types of scFv.
  • the peptide containing CDR of the present invention can be obtained by designing as a peptide having the amino acid sequence of CDR of VH or VL of the antibody of the present invention.
  • ADCC activity measurement The “ADCC activity” in the present specification can be measured by any method as long as it is a known method for measuring ADCC activity, but preferably means the activity measured by the following procedure.
  • Target cell line eg, human osteosarcoma cell line
  • a suitable medium eg, a medium containing 10% fetal bovine serum containing equal amounts of Ham F12 medium and Dulbecco MEM medium.
  • the cells are seeded so as to have ⁇ 10 3 to 1 ⁇ 10 5 cells / well and cultured at 37 ° C. for 12 to 48 hours.
  • a test antibody or a control antibody an antibody known not to show ADCC activity.
  • an anti-GST antibody is added so as to be 0.1 to 1.0 ⁇ g / well.
  • T cells prepared in advance are added to each well and allowed to react at 37 ° C. for 8 to 24 hours. After the reaction, each well is washed with a culture medium, and a new medium and an MTS reagent are added. After culturing at 37 ° C. for 1 to 12 hours, the absorbance at 490 nm is measured.
  • the ADCC activity (%) is calculated by 100 ⁇ ((absorbance of test antibody) / (absorbance of control antibody)) ⁇ 100 (%) based on the obtained absorbance value.
  • the “measured value serving as an index of ADCC activity” means a measured value measured by the above method.
  • CDC activity can be measured by any method as long as it is a known method for measuring CDC activity, but preferably means the activity measured by the following procedure.
  • Target cell line prepared to be 10 ⁇ 10 3 to 10 ⁇ 10 6 cells / mL in an appropriate medium (for example, Ham F12 medium containing 10% fetal bovine serum and Dulbecco MEM medium mixed in equal amounts) (For example, human small cell lung cancer strain SY) was seeded, and an appropriate medium (for example, Ham F12 medium and Dulbecco MEM medium) in which a test antibody or a control antibody (for example, anti-GST antibody) was dissolved was mixed in an equal amount.
  • an appropriate medium for example, Ham F12 medium and Dulbecco MEM medium
  • a test antibody or a control antibody for example, anti-GST antibody
  • the dissociation constant can be measured by any method as long as it is a known method for measuring the dissociation constant, but preferably means a numerical value measured by the following method.
  • the PDGFR ⁇ extracellular region (1-514 amino acids) and mouse IgG constant region fusion protein (PDGFR ⁇ -Fc) were immobilized on the CM5 chip, Flow, Kon, Koff are measured, and the dissociation constant (KD value) is determined.
  • the antibody of the present invention can be used as a medicine based on knowledge usually used by those skilled in the art of antibody medicine. Therefore, in one aspect, the present invention relates to a pharmaceutical composition containing the antibody of the present invention as an active ingredient.
  • the pharmaceutical composition of the present invention may be a therapeutic or prophylactic agent for diseases caused by cell proliferation, for example, a therapeutic or prophylactic agent for tumors (cancer and / or sarcoma). Can do.
  • the pharmaceutical composition of the present invention comprises melanoma, small cell lung cancer, non-small cell lung cancer, glioma, liver cancer, prostate cancer, endometrial cancer, kidney cancer, head and neck cancer, mesothelioma, sarcoma, Bile duct cancer, small intestine adenocarcinoma, childhood malignant tumor, squamous cell carcinoma, gastrointestinal stromal tumor, esophageal cancer, thyroid cancer, bladder cancer, colon cancer, gastric cancer, pancreatic cancer, breast cancer, liver cancer, lung cancer, breast cancer, neuroblast It may be used as a therapeutic or preventive for cell tumor (neuroblastoma), glioblastoma (glioblastoma), uterine cancer, ovarian cancer, Wilms tumor, chronic myelogenous leukemia, Philadelphia chromosome positive chronic myelogenous leukemia it can.
  • the administration site include oral administration, buccal administration, intratracheal administration, subcutaneous administration, intramuscular administration, and intravascular (intravenous) administration.
  • the pharmaceutical composition can be, for example, an injection, capsule, tablet, syrup, or granule preparation.
  • the antibody of the present invention may be administered alone or together with a pharmacologically acceptable single substance.
  • Example 1 Production of Monoclonal Antibody against Human PDGFR ⁇
  • PDGFR ⁇ extracellular region (1-514 amino acids) and mouse IgG2a constant region fusion protein (PDGFR ⁇ -Fc) were used as an immunizing antigen. This was used to immunize BALB / c mice. After four immunizations of mice, the spleen monocytes of the immunized mice and a fusion partner, X63-Ag8-653, were subjected to polyethylene glycol-mediated cell fusion, and the literature (J. Immunol. 146: 3721-3728). ) Hybridomas were selected by the method described. Selection was performed by selecting cells that respond to immobilized PDGFR ⁇ -Fc.
  • Example 2 Measurement of Western blotting, immunoprecipitation, FACS, and dissociation constant
  • the dissociation constant was measured by Western blotting, immunoprecipitation, FACS, and BIACORE according to the following procedure.
  • Western blotting was performed according to a conventional method of Western blotting (for example, “Molecular Biology Basic Experimental Method”, Nankodo).
  • the human osteosarcoma cell line MG-63 ATCC, CRL-1427
  • MG-63 ATCC, CRL-1427
  • the recovered antibody was subjected to SDS polyacrylamide electrophoresis. After the gel was transferred to a PVDF membrane (Millipore, IPVH00010), human PDGFR ⁇ polyclonal antibody C-20 (Santa Cruz Biotechnology, sc-338) was reacted, and an anti-rabbit IgG HRP-labeled antibody (Immuno-Biological Laboratories, 17502). ). The results are shown in Table 1. In the table, ⁇ indicates strong positive.
  • FACS Fluorescence Activated Cell Sorting
  • the cells were adjusted to 2 ⁇ 10 6 cells / mL with staining buffer (PBS, 0.1% NaN 3 , 5% fetal bovine serum, 1 mM EDTA) (hereinafter referred to as “SB”), and then 5 ⁇ g / mL in advance.
  • 50 ⁇ L was added to a 96-well plate (FALCON, 353077) into which 50 ⁇ L of each antibody obtained in Example 1 prepared in 1 was dispensed. After reacting at 4 ° C. for 30 minutes, the plate was washed with SB, and anti-mouse IgG FITC-labeled antibody (Immuno-Biological Laboratories, Inc., 17621) was added. After reacting at 4 ° C.
  • Example 3 Measurement of neutralizing activity It was confirmed that the human osteosarcoma cell line MG-63 (ATCC, CRL-1427) expresses PDGFR ⁇ (results not shown).
  • the neutralizing activity of the antibody obtained in Example 1 was measured using human osteosarcoma cell line MG-63.
  • the human osteosarcoma cell line MG-63 was added to a 6-well plate (Corning Inc, 3506) in 2 ⁇ 10 5 cells in a medium containing 10% fetal calf serum mixed with equal amounts of Ham F12 medium and Dulbecco MEM medium. / Well, and cultured at 5% CO 2 and 37 ° C. for 24 hours.
  • PDGFR ⁇ was detected with a human PDGFR ⁇ polyclonal antibody C-20 (Santa Cruz Biotechnology, sc-338) and a phosphotyrosine antibody 4G10 (Millipore, 05-321). did.
  • Example 1 suppressed the phosphorylation of PDGFR ⁇ by PDGF-AA as compared with the case where normal mouse serum (Normal Mouse IgG) was administered.
  • the antibodies of clone numbers 5A1, 22A1 and 24A1 showed remarkable phosphorylation neutralizing activity.
  • Each antibody obtained in Example 1 was shown to have neutralizing activity against PDGFR ⁇ and suppress signal transduction downstream of PDGFR ⁇ .
  • Example 4 ADCC activity measurement The ADCC activity of the antibody obtained in Example 1 was measured using human osteosarcoma cell line MG-63 (ATCC, CRL-1427).
  • A Preparation of T cells T cells used in ADCC activity measurement were prepared by the following procedure. Spleen cells collected from nude mice (Nippon Charles River, Inc., 9238301 CAnN.Cg-Foxn1nu / CrlCrlj (BALB / c nude mice)) were separated using a column (Polysciences Inc., 21759) filled with nylon wool. did.
  • T cell fraction The obtained non-adsorbed fraction (T cell fraction) was added with concanavalin A (Vector Laboratories Inc., L-1000) at a final concentration of 5 ⁇ g / mL and stimulated at 37 ° C. for 3 hours, and then with Ham F12 medium. It was prepared to be 1 ⁇ 10 6 cells / mL in a medium mixed with an equal volume of Dulbecco MEM medium. The prepared T cells were used as T cells in the following ADCC activity measurement test.
  • concanavalin A Vector Laboratories Inc., L-1000
  • an anti-GST antibody 14C1 prepared according to a conventional method and adjusted to 0.4 ⁇ g / mL was added to 50 ⁇ L / well. Thereafter, T cells prepared in advance were added to each well at 50 ⁇ L / well and reacted at 37 ° C. for 12 hours. After the reaction, each well was washed with a culture medium, added with 100 ⁇ L of the same medium and 20 ⁇ L of MTS reagent (Promega, G3580), cultured at 37 ° C. for 2 hours, and then measured for absorbance at 490 nm (reference wavelength: 650 nm). The ADCC activity (%) was calculated by 100 ⁇ (each antibody administration group / negative control) ⁇ 100 (%).
  • Example 5 Measurement of CDC activity Human small cell lung cancer strain SY in which PDGFR ⁇ expression was confirmed (provided by Aichi Cancer Center, see Br. J. Cancer (1991), 63, Suppl. XIV, 24-28). Then, the CDC activity of the antibody obtained in Example 1 was measured.
  • Human small cell lung cancer strain SY (provided by Aichi Prefectural Cancer Center) prepared to be 4 ⁇ 10 5 cells / mL in a medium in which Ham F12 medium containing 10% fetal bovine serum and Dulbecco MEM medium are mixed in equal amounts , Br. J. Cancer (1991), 63, Suppl.
  • XIV, 24-28 is seeded in a 96-well plate (Corning Inc., 3598) at 50 ⁇ L / well, Ham F12 medium, Dulbecco MEM medium, etc.
  • Each antibody obtained in Example 1 adjusted to 4 ⁇ g / mL or 20 ⁇ g / mL with a medium mixed in an amount was added at 50 ⁇ L / well so that the final concentration was 1 ⁇ g / mL or 5 ⁇ g / mL.
  • anti-GST antibody 40B3 prepared according to a conventional method and adjusted to 4 ⁇ g / mL or 20 ⁇ g / mL was added to a concentration of 50 ⁇ L / well.
  • the culture supernatant was collected, and the degree of cell damage was measured using a lactate dehydrogenase (LDH) measurement reagent (Promega, G1780).
  • LDH lactate dehydrogenase
  • the CDC activity (%) was calculated by (each antibody administration group / antibody non-administration group) ⁇ 100 (%).
  • Example 6 Measurement of anti-tumor effect The anti-tumor effect of the antibody prepared in Example 1 was confirmed in vivo using a nude mouse transplanted human tumor model (Xenograft). 1 ⁇ 10 7 SY cells (provided by Aichi Cancer Center, Br.J) Cancer (1991), 63, Suppl. XIV, 24-28). Two weeks later, it was confirmed that tumors were formed, and 400 ⁇ g each of the antibody prepared in Example 1 was administered by intravenous tail injection. As a negative control, 400 ⁇ g of GST antibody 14C1 was used. Each antibody was administered once a week to 5 nude mice. The antitumor effect was measured by measuring the tumor size once a week.
  • Example 7 Measurement of dose-dependent antibody volume of antitumor effect 1 ⁇ 10 7 subcutaneously in the back of nude mice (Charles River Japan, 9238301 CAnN.Cg-Foxn1nu / CrlCrlj (BALB / c nude mice)) SY cells (provided by Aichi Cancer Center, Br. J. Cancer (1991), 63, Suppl. XIV, 24-28) were transplanted. Two weeks later, it was confirmed that tumors were formed, and 1 mg, 400 ⁇ g, and 100 ⁇ g of the clone No. 24A1 antibody prepared in Example 1 (hereinafter referred to as “24A1 antibody”) were administered by tail vein injection. As a negative control, 400 ⁇ g of GST antibody 40B3 was used. Each antibody was administered once a week to 5 nude mice. The antitumor effect was measured by measuring the tumor size once a week.
  • Example 8 Epitope mapping
  • the epitopes of the 24A1 antibody and the 21A1 antibody confirmed to have antitumor effects were determined by epitope mapping using a dot blot.
  • a gene encoding the extracellular region (1-514 amino acids) (SEQ ID NO: 14) of human PDGFR ⁇ and genes encoding various deletion mutants deleted from the C-terminus of the region were prepared.
  • the generated deletion mutant genes were human PDGFR ⁇ 1-106 amino acids (PDGFR ⁇ 106-Fc), 1-213 amino acids (PDGFR ⁇ 213-Fc), 1-311 amino acids (PDGFR ⁇ 311-Fc), 1-409 amino acids (PDGFR ⁇ 409-Fc).
  • COS cells (ATCC, CRL-1650) are transfected with expression vectors into which these genes have been introduced, and cultured for 2 days in serum-free Dulbecco MEM medium (Immuno-Biological Laboratories, Inc., 33252), and the culture supernatant is recovered. did. The collected culture supernatant was ultra-concentrated to a 10-fold concentration and dot-blotted onto a PVDF membrane (Millipore, IPVH00010). After reacting with 21A1 antibody or 24A1 antibody, detection was performed with an anti-mouse Ig ⁇ chain HRP-labeled antibody (Southern Biotech, 1050-05).
  • Results are shown in FIG. It was shown that the 21A1 antibody has an epitope in the 106-213 amino acid (SEQ ID NO: 2) region of PDGFR ⁇ , and the 24A1 antibody has an epitope in the 213-311 amino acid (SEQ ID NO: 3) region.
  • Example 9 Antibody Sequencing
  • the heavy chain hereinafter referred to as “Hc”
  • the light chain hereinafter referred to as “Lc”
  • MRNA was extracted from the hybridoma producing the 24A1 antibody to prepare cDNA.
  • 5′-Rapid amplification cDNA end 5′-RACE
  • the full length cDNAs were cloned using primers specific for Hc and Lc.
  • the determined gene sequences of Hc and Lc were as shown in SEQ ID NO: 29 and SEQ ID NO: 31, and the amino acid sequences were as shown in SEQ ID NO: 30 and SEQ ID NO: 32, respectively.
  • An expression vector was prepared by incorporating the cloned Hc and Lc genes of 24A1 antibody into pcDNA3.1 (+) (Invitrogen, V790-20), and expression was confirmed by a transient expression test.
  • COS-1 cells (ATCC, CRL-1650) were transfected with Hc expression vector alone, Lc expression vector alone, or both Hc expression vector and Lc expression vector. After culturing in serum-free Dulbecco MEM medium (Immuno-Biological Laboratories, Inc., 33252) for 2 days, the culture supernatant and cells were recovered. The culture supernatant was ultra-concentrated to a 10-fold concentration and subjected to SDS-PAGE polyacrylamide gel electrophoresis. The gel was transferred to a PVDF membrane (Millipore, IPVH00010), and then detected with an anti-mouse IgG HRP-labeled antibody (Immuno-Biological Laboratories, Inc., 17504).
  • EIA method was performed. It was. Human PDGFR ⁇ -Fc fusion protein (PDGFR ⁇ extracellular region [1-514 amino acids] and mouse IgG2a constant region fusion protein) and human c-kit-Fc fusion protein (c-Kit extracellular region [1-504 amino acids] and mouse IgG2a The constant region fusion protein) was immobilized on a 96-well plate (Nalge Nunc International KK, 430341).
  • COS-1 cell culture supernatant in which Hc and Lc of 24A1 antibody were co-expressed was serially diluted, and 50 ⁇ L was added to each well. After reacting at 37 ° C. for 2 hours, an orthophenylenediamine ⁇ 2HCl (OPD) (SIGMA, P8787) solution washed with PBS added with tween 20 to a final concentration of 0.05% and adjusted to 400 ⁇ g / mL 100 ⁇ L was added to cause coloration.
  • OPD orthophenylenediamine ⁇ 2HCl
  • Example 11 Humanization of 24A1 antibody
  • the gene was modified for the purpose of humanizing the 24A1 antibody cloned in Example 9.
  • Human Hc and Lc genes having homology with the gene sequences of the Hc and Lc variable regions of 24A1 antibody were searched by IgBLAST of National Center for Biotechnology Information (NCBI). Hc had the highest homology with IGHV4-30-4 (SEQ ID NO: 27) and Lc with IGKV1D-12 (SEQ ID NO: 28). Based on this sequence, the Hc and Lc genes of the 24A1 antibody were modified and humanized at the amino acid level.
  • FIG. 9 shows a comparison of the amino acid sequences of Hc
  • FIG. 10 shows a comparison of the amino acid sequences of Lc.
  • each CDR is indicated by an underline.
  • Each CDR is as follows.
  • Heavy chain CDR1 SDYAWN (SEQ ID NO: 4) Heavy chain CDR2: YISYSGSTSYNPLSKS (SEQ ID NO: 5) Heavy chain CDR3: RDYRYGYWYFDV (SEQ ID NO: 6) Light chain CDR1: HASQNIHVWLT (SEQ ID NO: 7) Light chain CDR2: KASNLHT (SEQ ID NO: 8) Light chain CDR3: QQGQSYPWT (SEQ ID NO: 9)
  • the CDR sequence is a sequence that determines antigen specificity, and the surrounding amino acid sequence plays an important role in taking the three-dimensional structure presenting the CDR to the antigen. Therefore, the 5 amino acids near the CDR remain mouse type. And the other framework regions (hereinafter referred to as “FR”) were replaced with human amino acid sequences.
  • FR is as follows.
  • Heavy chain FR1 DVQLQESGPGLVKPSQTLSLTCTVSGYSIT (SEQ ID NO: 15) Heavy chain FR2: WIRQFPGNNKLEVG (SEQ ID NO: 16) Heavy chain FR3: RISITRDTSKNQFFFLQLNSVTTEDTATYYCAR (SEQ ID NO: 17) Heavy chain FR4: WGAGTTVTVSSAK (SEQ ID NO: 18) Light chain FR1: DIQMNQSPSSLSASLGDTITTC (SEQ ID NO: 19) Light chain FR2: WYQQKPGNIIPKLLIY (SEQ ID NO: 20) Light chain FR3: GVPSRFSGSGSGGTGFLTTISSLQPEDIATYYC (SEQ ID NO: 21) Light chain FR4: FGGGTKLEIK (SEQ ID NO: 22)
  • the amino acid sequence after substitution is indicated by “Hu PDGFRa (24A1)”.
  • the amino acid sequence of the heavy chain after substitution is shown in SEQ ID NO: 24, and the amino acid sequence of the light chain is shown in SEQ ID NO: 26.
  • gene sequences corresponding to the amino acid sequences of the humanized Hc variable region and the humanized Lc variable region were prepared.
  • the produced artificial genes Hu PDGFRa (24A1) Hc and Hu PDGFRa (24A1) Lc were used as human antibody constant region expression vectors SRH (human IgG1 constant region) and SRL-neo (human Ig ⁇ chain constant region) (The Journal of Immunology, Vol. 157, Issue 7: 3148-3152) to prepare a humanized anti-PDGFRa antibody (24A1) expression vector.
  • Hc and Lc of the prepared humanized anti-PDGFRa antibody (24A1) were transient expression test.
  • an expression vector chimeric anti-PDGFRa antibody (24A1)) in which the Hc and Lc variable regions of a mouse anti-PDGFR ⁇ antibody (24A1 antibody) were respectively incorporated into SRH and SRL-neo was prepared and expressed.
  • COS-1 cells (ATCC, CRL-1650) were transfected with Hc, Lc alone or a mixture of Hc and Lc.
  • Example 12 Activity measurement of humanized anti-PDGFR ⁇ antibody (24A1) EIA was performed to confirm the activity of humanized anti-PDGFR ⁇ antibody (24A1).
  • Human PDGFR ⁇ -Fc fusion protein (PDGFR ⁇ extracellular region [1-514 amino acids] and mouse IgG2a constant region fusion protein) and human FLT4-Fc fusion protein (FLT4 extracellular region [1-766 amino acids] and mouse IgG2a constant region fusion protein)
  • a 96-well plate Naalge Nunc International KK, 430341. According to the method described in Example 10, the COS-1 cell culture supernatant in which Hc and Lc genes were co-expressed was serially diluted and added to each well.
  • the results are shown in Table 3.
  • the humanized PDGFRa antibody (24A1) and human chimeric PDGFRa antibody (24A1) in the culture supernatant reacted only with the PDGFR ⁇ -Fc fusion protein, and no reaction with the FLT4-Fc fusion protein was confirmed. This confirmed the antigen specificity of the humanized PDGFR ⁇ antibody (24A1). Further, it was shown that the humanized PDGFR ⁇ antibody (24A1) has the same activity as the human chimeric PDGFR ⁇ antibody (24A1) having a mouse-type variable region.
  • Example 13 Determination of antibody sequence
  • Hc heavy chain
  • Lc light chain
  • MRNA was extracted from the hybridoma producing the 21A1 antibody to prepare cDNA.
  • 5′-Rapid amplification cDNA end 5′-RACE was performed to determine the base sequences of the 5 ′ ends of the Hc and Lc genes.
  • the full length cDNAs were cloned using primers specific for Hc and Lc.
  • the determined gene sequences of Hc and Lc were as shown in SEQ ID NO: 39 and SEQ ID NO: 41, and the amino acid sequences were as shown in SEQ ID NO: 40 and SEQ ID NO: 42, respectively (FIGS. 12 and 13).
  • each CDR is indicated by an underline. Each CDR was as follows.
  • Heavy chain CDR1 IFWMS (SEQ ID NO: 33) Heavy chain CDR2: EINPDSTINYTPSLKD (SEQ ID NO: 34) Heavy chain CDR3: QRFGGPY (SEQ ID NO: 35) Light chain CDR1: KASQDVSTAVA (SEQ ID NO: 36) Light chain CDR2: SASYRYT (SEQ ID NO: 37) Light chain CDR3: QQYSTPYT (SEQ ID NO: 38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps contre PDGFRα, et leur utilisation. L'invention concerne spécifiquement un anticorps anti-PDGFRα qui reconnaît une séquence d'acides aminés dans une séquence d'acides aminés de la 106e à la 311e position dans un PDGFRα en tant qu'épitope, un anticorps anti-PDGRFα qui présente une activité de cytotoxicité cellulaire dépendante des anticorps (ADCC) supérieure ou égale à 50 % dans des lymphocytes T, et un anticorps anti-PDGFRα qui présente une activité de cytotoxicité dépendante du complément (CDC) supérieure ou égale à 15 %. L'invention concerne également l'ADN qui code pour les anticorps susmentionnés et une composition pharmaceutique qui comprend les anticorps susmentionnés en tant que composant efficace.
PCT/JP2011/003603 2010-06-24 2011-06-23 Anticorps anti-récepteur de pdgf Ceased WO2011161970A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010143397A JP2013177317A (ja) 2010-06-24 2010-06-24 抗ｐｄｇｆ受容体抗体
JP2010-143397 2010-06-24

Publications (1)

Publication Number Publication Date
WO2011161970A1 true WO2011161970A1 (fr) 2011-12-29

Family

ID=45371175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/003603 Ceased WO2011161970A1 (fr) 2010-06-24 2011-06-23 Anticorps anti-récepteur de pdgf

Country Status (2)

Country Link
JP (1) JP2013177317A (fr)
WO (1) WO2011161970A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017900A1 (fr) * 2013-08-05 2015-02-12 St. Vincent's Institute Of Medical Research Traitement par anticorps pour maladie associée à la bêta-amyloïde
WO2022226105A1 (fr) * 2021-04-20 2022-10-27 The Trustees Of Columbia University In The City Of New York Antiviraux contre le virus de la rougeole

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011041A1 (fr) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. Composition d'anticorps génétiquement modifié
JP2009501141A (ja) * 2005-06-17 2009-01-15 イムクローン システムズ インコーポレイテッド 転移性骨癌の治療のための受容体アンタゴニスト
WO2009142186A1 (fr) * 2008-05-20 2009-11-26 株式会社カネカ Composition cytotoxique
JP2010500872A (ja) * 2006-08-03 2010-01-14 アストラゼネカ アクチボラグ Ｐｄｇｆｒ−アルファに対して指向性のターゲテッド結合剤およびその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501141A (ja) * 2005-06-17 2009-01-15 イムクローン システムズ インコーポレイテッド 転移性骨癌の治療のための受容体アンタゴニスト
WO2007011041A1 (fr) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. Composition d'anticorps génétiquement modifié
JP2010500872A (ja) * 2006-08-03 2010-01-14 アストラゼネカ アクチボラグ Ｐｄｇｆｒ−アルファに対して指向性のターゲテッド結合剤およびその使用
WO2009142186A1 (fr) * 2008-05-20 2009-11-26 株式会社カネカ Composition cytotoxique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
E TANIGUCHI ET AL.: "PDGFR-A is a Therapeutic Target in Alveolar Rhabdomyosarcoma", ONCOGENE, vol. 27, no. 51, 2008, pages 1 - 18 *
NICK LOIZOS ET AL.: "Targeting the platelet- derived growth facto rreceptor a with a neutralizing human monoclonal antibody inhibits the etgrowth of tumor xenografts: Implications as a potential therapeutic target", MOL CANCER THER, vol. 4, no. 3, 2005, pages 369 - 379 *
PEGGY STOCK ET AL.: "Platelet-derived growth factor receptor-a: a novel therapeutic target in human hepatocellular cancer", MOL CANCER THER, vol. 6, no. 7, 2007, pages 1932 - 1941 *
ROBERT L. SHIELDS ET AL.: "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody- dependent Cellular Toxicity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 30, 2002, pages 26733 - 26740 *
TOYOHIDE SHINKAWA ET AL.: "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 5, 2003, pages 3466 - 3473 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017900A1 (fr) * 2013-08-05 2015-02-12 St. Vincent's Institute Of Medical Research Traitement par anticorps pour maladie associée à la bêta-amyloïde
US9908933B2 (en) 2013-08-05 2018-03-06 St. Vincent's Institute Of Medical Research Antibody therapy for amyloid beta disease
WO2022226105A1 (fr) * 2021-04-20 2022-10-27 The Trustees Of Columbia University In The City Of New York Antiviraux contre le virus de la rougeole

Also Published As

Publication number Publication date
JP2013177317A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
JP7562528B2 (ja) 抗体及びその用途
TWI821474B (zh) Ｃｄ３抗體及其藥物用途
JP6060073B2 (ja) Ｃｄ１２２に対する抗体
JP2021524250A (ja) Ｐｓｍａ結合剤及びその使用
JP2024091842A (ja) 抗ｃｄ３抗体及び該抗体を含む分子
KR20210137477A (ko) 이중기능성 융합 단백질 및 그것의 제약학적 용도
KR20210040827A (ko) 항 tigit 항체 및 그 용도
TWI745670B (zh) 抗cd27抗體、其抗原結合片段及其醫藥用途
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
WO2020114479A1 (fr) Molécule de protéine multispécifique
WO2019091449A1 (fr) Anticorps cd96, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée
KR20200012920A (ko) 항-cd40 항체, 이의 항원 결합 단편 및 이의 의학적 용도
CN110770252A (zh) 抗p53抗体
WO2020151761A1 (fr) Anticorps bispécifique se liant à pd-l1 et ox40
KR20240109605A (ko) 항-인간 cd3 항체 및 이의 응용
JP6872756B2 (ja) 抗Ｍｙｌ９抗体
CN116769034B (zh) 抗cd73抗体或其抗原片段及其应用
TWI801350B (zh) 自體免疫疾病治療用抗體及其製造方法
JP2024523514A (ja) 抗ｃｄ４０抗体、その抗原結合断片及び医薬用途
WO2011161970A1 (fr) Anticorps anti-récepteur de pdgf
JP2023511189A (ja) Ｓｅｍｇ２抗体およびその使用
RU2809746C2 (ru) Гуманизированное моноклональное антитело против vegf
RU2790326C2 (ru) Анти-сd3-антитело и молекула, содержащая это антитело
JP7384668B2 (ja) 細胞傷害性ｔ細胞枯渇用組成物
WO2025214468A1 (fr) Anticorps anti-il-15 et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11797858

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11797858

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP